Interstitial Lung Disease in Polymyositis and Dermatomyositis

Kathryn Long, Sonye K. Danoff

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

The idiopathic inflammatory myopathies (IIMs), including polymyositis (PM) and dermatomyositis (DM), are autoimmune connective tissue diseases with variable degrees of muscle inflammation and systemic involvement. Interstitial lung disease (ILD) is a common complication of the IIMs and is associated with increased mortality. Many patients with PM/DM have myositis-specific and myositis-associated antibodies (MSA/MAAs) that result in distinct clinical phenotypes. Among these MSAs, anti-aminoacyl-tRNA antibodies and anti-melanoma differentiation factor 5 antibodies have high rates of ILD. Corticosteroids are the mainstay of treatment, although the addition of other immunosuppressive therapy is typically necessary to achieve disease control.

Original languageEnglish (US)
Pages (from-to)561-572
Number of pages12
JournalClinics in Chest Medicine
Volume40
Issue number3
DOIs
StatePublished - Sep 2019

Keywords

  • Dermatomyositis
  • Interstitial lung disease
  • Myositis
  • Polymyositis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Interstitial Lung Disease in Polymyositis and Dermatomyositis'. Together they form a unique fingerprint.

Cite this